Pitolisant

Routes
Oral (PO)
Half-Life (t½)
PO: 20h
Formula
C17H26ClNO
Molecular Weight
295.8 g/mol
PubChem CID
9948102
Aliases
Wakix

Pharmacological Mechanism

Histamine H3 receptor antagonist / inverse agonist; raises central histamine to promote wakefulness (narcolepsy). CYP2D6 + CYP3A4 metabolism.

Half-Life & Elimination Curve (PO: 20h)

100%50%25%12.5%0%0h0×t½20h1×t½40h2×t½60h3×t½3.3d4×t½4.2d5×t½0×t½ (0h): 100% remaining (~20.3 µg/L)1×t½ (20h): 50% remaining (~10.1 µg/L)2×t½ (40h): 25% remaining (~5.07 µg/L)3×t½ (60h): 12.5% remaining (~2.54 µg/L)4×t½ (3.3d): 6.3% remaining (~1.27 µg/L)5×t½ (4.2d): 3.1% remaining (~0.634 µg/L)
Plasma (PO)t½ Decay (20h)Effect Site (ke0)
  • 0×t½0h100% (20.3 µg/L)
  • 1×t½20h50% (10.1 µg/L)
  • 2×t½40h25% (5.07 µg/L)
  • 3×t½60h12.5% (2.54 µg/L)
  • 4×t½3.3d6.3% (1.27 µg/L)
  • 5×t½4.2d3.1% (0.634 µg/L)
Elimination t½20h (PO)
Rate Constant (ke)0.0347 h⁻¹
Time to Peak (Tmax)3.48h
Est. Peak (Cmax)20.3 µg/L
Clearance (CL)24.3 L/h
97% Washout (5×t½)4.2d

Dosing Guidelines

Pharmacokinetic Parameters

Receptor Binding & Occupancy

Target Organ Systems

Notes

PK from FDA prescribing information (DailyMed setid 8daa5562-824e-476c-9652-26ceef3d4b0e): oral absorption ~90% (F 0.9), Vd 5–10 L/kg (~700 L), terminal t½ ~20 h, Tmax 3.5 h, CYP2D6/3A4. ka_hr 1.0 derived from Tmax 3.5 h (ke from t½ 20 h).

Chemical Structure & Identifiers

References